HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Surrogate endpoints in clinical trials of chronic kidney disease progression: moving from single to multiple risk marker response scores.

AbstractPURPOSE OF REVIEW:
There is increased interest in developing surrogate endpoints for clinical trials of chronic kidney disease progression, as the established clinically meaningful endpoint end-stage renal disease requires large and lengthy trials to assess drug efficacy. We describe recent developments in the search for novel surrogate endpoints.
RECENT FINDINGS:
Declines in estimated glomerular filtration rate (eGFR) of 30% or 40% and albuminuria have been proposed as surrogates for end-stage renal disease. However, changes in eGFR or albuminuria may not be valid under all circumstances as drugs always have effects on multiple renal risk markers. Changes in each of these other 'off-target' risk markers can alter renal risk (either beneficially or adversely), and can thereby confound the relationship between surrogates that are based on single risk markers and renal outcome. Risk algorithms that integrate the short-term drug effects on multiple risk markers to predict drug effects on hard renal outcomes may therefore be more accurate. The validity of these risk algorithms is currently investigated.
SUMMARY:
Given that drugs affect multiple renal risk markers, risk scores that integrate these effects are a promising alternative to using eGFR decline or albuminuria. Proper validation is required before these risk scores can be implemented.
AuthorsBauke Schievink, Peter G M Mol, Hiddo J Lambers Heerspink
JournalCurrent opinion in nephrology and hypertension (Curr Opin Nephrol Hypertens) Vol. 24 Issue 6 Pg. 492-7 (Nov 2015) ISSN: 1473-6543 [Electronic] England
PMID26335552 (Publication Type: Journal Article, Review)
Chemical References
  • Biomarkers
Topics
  • Albuminuria (metabolism)
  • Animals
  • Biomarkers (analysis)
  • Disease Progression
  • Glomerular Filtration Rate (physiology)
  • Humans
  • Kidney (physiopathology)
  • Renal Insufficiency, Chronic (diagnosis, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: